Streetbeat News

Analyst Ratings

AMD

INTC

NVDA

Nvidia Corp (NASDAQ:NVDA) has seen its stock more than triple in 2023, reaching $488.30 from $143.15. The company's market cap is now $1.2 trillion, with increased earnings and revenue. Nvidia's success is linked to high demand for its graphics cards used in AI training. Technical indicators are bullish, with the 50-day SMA crossing over the 100-day SMA. However, Nvidia's forward P/E of 39.70, while lower than peers AMD and Intel, is still high, and a bearish divergence in the OBV indicator suggests potential consolidation. Nvidia's 2024 guidance is optimistic, with expected growth in data center GPU shipments.

Portfolio Pulse from Surbhi Jain

December 26, 2023 | 2:02 pm

ETH-USD

SOL-USD

Cryptocurrency analyst Altcoin Sherpa has increased his holdings in Solana (SOL), despite acknowledging it might not be the best time to buy. He believes SOL will continue its upward trend into 2024, citing its affordability and accessibility for new crypto users. Google search volume for 'Solana' has surged 250% in two months. Solana's price is currently at $122.64, up 7.73% in the last 24 hours, and has increased over 1,000% since the start of the year.

Portfolio Pulse from Mehab Qureshi

December 26, 2023 | 1:54 pm

DHT

ETRN

VTS

The article discusses three high-yielding dividend stocks in the energy sector recommended by Wall Street's most accurate analysts. Vitesse Energy, Inc. (VTS) has a dividend yield of 8.94% and received Buy ratings with price targets of $27 and $30.5, despite recent downbeat earnings. DHT Holdings, Inc. (DHT) offers a 10.96% dividend yield but was downgraded to Hold with price targets of $11 and $10 after posting weaker-than-expected results. Equitrans Midstream Corporation (ETRN) has a 5.89% yield and was downgraded to Underweight with a $10 price target, although it reported upbeat earnings.

Portfolio Pulse from Avi Kapoor

December 26, 2023 | 1:29 pm

LGF

LGF/B

Rosenblatt analyst Barton Crockett has maintained a Buy rating on Lions Gate Entertainment (NYSE:LGF) and increased the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 1:09 pm

ALVR

CMS

CTSH

FPI

HBAN

KRTX

MOD

OHI

PAYX

Wall Street analysts have updated their price targets and ratings for several companies. Karuna Therapeutics' target was raised but downgraded to Neutral. AlloVir's target was cut significantly and downgraded to Underperform. Farmland Partners, Huntington Bancshares, Cognizant Technology Solutions, Modine Manufacturing, and CMS Energy had their targets raised with positive ratings. Paychex and Omega Healthcare Investors had their targets cut with neutral and hold ratings, respectively. Equillium's target was slashed but maintained a Buy rating.

Portfolio Pulse from Avi Kapoor

December 26, 2023 | 1:03 pm

MPWR

Rosenblatt analyst Hans Mosesmann maintains a Buy rating on Monolithic Power Systems (MPWR) and increases the price target from $550 to $750.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 1:02 pm

CMS

CMS Energy (NYSE:CMS) has received mixed ratings from 7 analysts in the past three months, with an average 12-month price target of $59.57, down 3.66% from previous estimates. The company faces revenue challenges with a -17.34% decline over 3 months, a below-average net margin of 10.4%, but strong ROE and ROA figures. It also has a high debt-to-equity ratio of 2.22. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance.

Portfolio Pulse from Benzinga Insights

December 26, 2023 | 1:00 pm

HBAN

Huntington Bancshares (NASDAQ:HBAN) received mixed analyst ratings in the past three months, with a recent average 12-month price target of $13.11, up from $12.94. Analysts from firms like Raymond James, RBC Capital, Goldman Sachs, Morgan Stanley, Barclays, JP Morgan, and Citigroup have updated their ratings and price targets, reflecting their views on the company's performance and market conditions. Huntington Bancshares, a regional bank holding company, faces revenue challenges and has a below-average net margin and ROA, but an above-average ROE and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 26, 2023 | 1:00 pm

OHI

Truist Securities analyst Michael Lewis has maintained a Hold rating on Omega Healthcare Investors (OHI) and reduced the price target from $34 to $31.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 12:52 pm